Drug Profile


Alternative Names: CLS-003; Furosemide/digoxin; ICVT; Ionic contra viral therapy

Latest Information Update: 07 Feb 2017

Price : $50

At a glance

  • Originator Henderson Morley
  • Developer Cutanea Life Sciences; Henderson Morley
  • Class Antihypertensives; Antivirals; Glycosides; Skin disorder therapies; Small molecules; Sulfanilamides
  • Mechanism of Action Potassium channel antagonists; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Recurrent respiratory papillomatosis
  • New Molecular Entity No

Highest Development Phases

  • Phase II Warts
  • Discontinued Herpes simplex virus infections; Human papillomavirus infections; Infectious keratoconjunctivitis

Most Recent Events

  • 07 Feb 2017 Phase-II development is ongoing in Netherlands (Topical)
  • 01 Aug 2015 Cutanea Life Sciences completes a phase II trial in Warts in the Netherlands (NCT02333643)
  • 03 Dec 2014 Discontinued - Phase-II for Human papillomavirus infections in United Kingdom (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top